Inhibition of FATP5 Alleviates the Progression of NASH by Increasing SCD1 Activity thereby Inhibiting Hepatic Ferroptosis (APASL 2025) - Feb 20, 2025 - Abstract #PP0420; "Erastin treatment in HepG2 cells and daily intraperitoneal injection of ferroptosis inhibitor Ferr-1 for 3 weeks in NASH mice were used to control ferroptosis... Our results suggest that FATP5 regulates lipid metabolism in NASH progression by controlling SCD1 expression. Inhibition of FATP5 effectively activates SCD1 and reduces lipid peroxidation, thereby preventing ferroptosis and relieving the progression of NASH. Overall, our findings might offer a promising target for NASH treatment in the future."
Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Dysfunction-Associated Steatohepatitis • SCD
|
|
Yiran Liu 1, 2; Jiazhi Liao 1, 2; Suhong Xia 1, 2
|